The phase 2 trial BNT111-01 (NCT04526899) [65] aims to assess the effect of a universal mRNA vaccine, BNT111, which encodes for four pre-specified proteins, NY-ESO-1, MAGE-A3, tyrosinase, and TPTE, in patients with unresectable melanoma. The gene discussed is MAGEA3; the disease is melanoma.